{"entity":{"id":"nct06542588","kind":"trial","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","aka":[],"tldr":"A phase 2 trial of serplulimab in colorectal cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.","summary":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC is a phase 2, interventional study registered as NCT06542588 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 29 participants, started 2024-07-19 and due to reach its primary completion in 2025-12. Interventions recorded: HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody). Conditions listed: Rectal Cancer. Primary outcome: complete response (CR) rate. Colorectal eligibility wording from the registry: \"Histologically confirmed Locally Advanced rectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06542588","url":"https://clinicaltrials.gov/study/NCT06542588"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06542588","phase":"2","setting":"A Multicenter, Single-arm, Open-label Clinical Trial of Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07 and Serplulimab in the Treatment for RAS/BRAF Wild Type Locally Advanced Rectal Cancer","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06542588/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}